Summary of KRYS Q2 2026 Earnings Call

1Key Financial Results and Metrics

Net Revenue: $119.2 million, a 24% increase from $96 million in Q2 2025, driven by global sales of VYJUVEK.

U.S. Revenue: $91.6 million for the quarter, with over 730 reimbursement approvals achieved.

Gross Margin: 95%, up from 93% in the prior year.

R&D Expenses: $14.5 million, flat compared to $14.4 million in Q2 2025.

G&A Expenses: Increased to $39.9 million from $35.1 million, attributed to headcount and commercial costs.

Net Income: $54.8 million, or $1.85 per basic share, compared to $38.3 million and $1.33 per basic share in Q2 2025.

Cash Position: Exceeded $1.1 billion in cash and investments.

2Strategic Updates and Business Highlights

Commercial Launch: Strong demand for VYJUVEK in Europe and Japan, with ongoing pricing and reimbursement discussions in multiple countries.

Clinical Pipeline: Two registrational studies underway for neurotrophic keratitis and ocular lesions in dystrophic epidermolysis bullosa (DEB). Additional studies in cystic fibrosis and Hailey-Hailey disease are progressing, with potential registrational developments expected in 2027.

Oncology Program: KB707 for non-small cell lung cancer (NSCLC) is on track for a registrational study next year, with promising early results.

Patient Engagement: Initiatives like VYJUVEK Voices and VYJUVEK Connections are enhancing patient support and education.

3Forward Guidance and Outlook

Revenue Expectations: Continued growth anticipated as pricing negotiations conclude and patient access expands.

Clinical Development: Plans to initiate at least two more registrational trials in 2027, aiming to transition into a multiproduct genetic medicines company.

Ongoing Negotiations: Expecting key outcomes from pricing discussions in Germany, Italy, and Spain by the end of 2026.

4Bad News, Challenges, or Points of Concern

European Revenue: Reported revenue in Europe and Japan was flat due to a reserve provision related to pricing negotiations, which may impact short-term financials.

Market Access Dynamics: Challenges in navigating country-specific requirements and reimbursement processes, particularly in Germany and France.

Competitive Pressures: Increased competition noted in the NK space, particularly from OXERVATE, which may affect market entry strategies.

5Notable Q&A Insights

Demand in Europe: Strong underlying demand exists, but precise patient estimates are challenging due to expanding treatment centers.

Hailey-Hailey Disease: The company is optimistic about the upcoming Phase I data and has established a natural history study to inform endpoints for future trials.

Commercial Opportunities: Continued focus on community settings in the U.S. to identify and treat more patients, with a healthy split between RDEB and DDEB patient populations.

Enrollment in Clinical Trials: Enrollment for NK and Hailey-Hailey studies is progressing well, with plans to leverage global sites for broader patient access. Overall, Krystal Biotech demonstrated solid financial performance and strategic progress in Q2 2026, while also acknowledging challenges in market access and competitive dynamics. The company remains optimistic about future growth driven by its expanding clinical pipeline and commercial initiatives.